NPI: 1902862824 · HARRODSBURG, KY 40330 · Critical Access Hospital · NPI assigned 04/21/2006
Authorized official SNAPP, WILLIAM controls 20+ related entities in our dataset. Read more
| Authorized Official | SNAPP, WILLIAM (CFO) |
| NPI Enumeration Date | 04/21/2006 |
Other providers sharing the same authorized official: SNAPP, WILLIAM
| Year | Claims | Total Paid |
|---|---|---|
| 2018 | 28,811 | $1.39M |
| 2019 | 28,667 | $1.71M |
| 2020 | 30,564 | $1.59M |
| 2021 | 50,785 | $2.17M |
| 2022 | 52,615 | $2.41M |
| 2023 | 44,245 | $2.53M |
| 2024 | 34,100 | $2.03M |
| Code | Description | Claims | Beneficiaries | Total Paid |
|---|---|---|---|---|
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 1,352 | 1,236 | $1.70M |
| 99284 | Emergency department visit for the evaluation and management, high severity | 7,393 | 6,631 | $1.29M |
| 99285 | Emergency department visit for the evaluation and management, high severity with immediate threat to life | 4,737 | 4,024 | $1.23M |
| 99283 | Emergency department visit for the evaluation and management, moderate severity | 10,037 | 9,050 | $846K |
| 80053 | Comprehensive metabolic panel | 27,445 | 20,832 | $793K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | 12,220 | 11,049 | $528K |
| 84443 | Thyroid stimulating hormone (TSH) | 10,145 | 9,661 | $472K |
| 87633 | Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets | 1,239 | 1,157 | $386K |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | 4,227 | 1,092 | $378K |
| 70450 | Computed tomography, head or brain; without contrast material | 928 | 819 | $377K |
| 80061 | Lipid panel | 8,865 | 8,426 | $339K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | 18,174 | 16,060 | $302K |
| 96375 | Therapeutic injection; each additional sequential IV push | 3,256 | 2,733 | $286K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | 272 | 242 | $280K |
| 0241U | Neonatal screening for hereditary disorders, genomic sequence analysis panel | 2,436 | 2,194 | $232K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | 4,159 | 3,579 | $231K |
| 71045 | Radiologic examination, chest; single view | 2,842 | 2,526 | $202K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | 3,490 | 3,011 | $201K |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | 4,216 | 2,744 | $167K |
| 71046 | Radiologic examination, chest; 2 views | 1,955 | 1,762 | $161K |
| 84439 | 5,212 | 4,844 | $149K | |
| 87631 | 1,216 | 1,068 | $141K | |
| 96361 | Intravenous infusion, hydration; each additional hour | 3,713 | 2,386 | $136K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 2,243 | 2,011 | $133K |
| 84484 | 2,868 | 2,122 | $126K | |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | 1,311 | 892 | $125K |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | 10,270 | 9,370 | $123K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | 3,139 | 2,981 | $121K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | 1,831 | 1,645 | $114K |
| 83036 | Hemoglobin; glycosylated (A1C) | 4,545 | 4,317 | $111K |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | 4,700 | 2,158 | $110K |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | 1,589 | 1,370 | $107K |
| 99211 | Office or other outpatient visit for the evaluation and management of an established patient, minimal severity | 1,959 | 1,210 | $100K |
| 36415 | Collection of venous blood by venipuncture | 13,631 | 7,480 | $93K |
| 87486 | 2,752 | 2,205 | $78K | |
| 82607 | 3,404 | 3,146 | $75K | |
| C9803 | Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | 12,807 | 10,081 | $71K |
| 87186 | 2,116 | 1,910 | $69K | |
| 87086 | Culture, bacterial; quantitative colony count, urine | 3,763 | 3,409 | $66K |
| 87077 | 2,875 | 2,099 | $65K | |
| 81001 | 4,796 | 4,282 | $63K | |
| 87581 | 2,362 | 2,134 | $62K | |
| 80306 | 1,017 | 901 | $55K | |
| 73630 | 865 | 787 | $52K | |
| 80048 | Basic metabolic panel (calcium, ionized) | 3,023 | 2,252 | $48K |
| 83690 | 2,470 | 2,213 | $47K | |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | 870 | 776 | $46K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | 2,503 | 1,987 | $43K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | 818 | 766 | $40K |
| 83605 | 896 | 776 | $38K | |
| 84703 | 1,993 | 1,839 | $37K | |
| 82728 | 1,655 | 1,554 | $37K | |
| 83540 | 1,679 | 1,583 | $35K | |
| 82043 | 1,950 | 949 | $31K | |
| 73610 | 457 | 424 | $29K | |
| 73560 | 428 | 360 | $29K | |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | 973 | 914 | $29K |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | 758 | 616 | $29K |
| 84153 | 1,129 | 1,097 | $28K | |
| 85027 | 3,557 | 3,335 | $27K | |
| 87661 | Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe | 773 | 707 | $27K |
| 83550 | 1,434 | 1,377 | $26K | |
| 87070 | 1,170 | 1,019 | $26K | |
| 80074 | 432 | 308 | $24K | |
| 83880 | 475 | 408 | $23K | |
| 73130 | 272 | 251 | $19K | |
| 11042 | Debridement, subcutaneous tissue (includes epidermis, dermis, and subcutaneous tissue); first 20 sq cm | 130 | 93 | $19K |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | 168 | 151 | $18K |
| 85379 | 342 | 324 | $17K | |
| 85610 | 1,417 | 1,130 | $17K | |
| 86140 | 1,072 | 941 | $17K | |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | 293 | 257 | $16K |
| 83735 | 871 | 795 | $15K | |
| 84481 | 471 | 453 | $14K | |
| 69436 | Tympanostomy (requiring insertion of ventilating tube), general anesthesia | 13 | 13 | $12K |
| 77067 | Screening mammography, bilateral, including computer-aided detection | 107 | 105 | $12K |
| J0131 | Injection, acetaminophen, not otherwise specified,10 mg | 713 | 618 | $11K |
| 97162 | 116 | 109 | $10K | |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | 44 | 38 | $9K |
| 86038 | 529 | 467 | $9K | |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | 161 | 127 | $8K |
| 85652 | 835 | 783 | $8K | |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | 14 | 13 | $8K |
| 72148 | Magnetic resonance imaging, lumbar spine; without contrast material | 13 | 12 | $7K |
| 84145 | 140 | 123 | $7K | |
| 73030 | 115 | 100 | $6K | |
| 80050 | General health panel | 222 | 170 | $6K |
| 87430 | 330 | 301 | $6K | |
| J3490 | Unclassified drugs | 888 | 432 | $6K |
| 86703 | 123 | 117 | $6K | |
| J7030 | Infusion, normal saline solution , 1000 cc | 509 | 313 | $6K |
| 97014 | 171 | 56 | $5K | |
| 82570 | 760 | 721 | $5K | |
| 87400 | 341 | 275 | $5K | |
| 87205 | 401 | 345 | $5K | |
| 73110 | 73 | 66 | $4K | |
| 82150 | 189 | 169 | $4K | |
| 85730 | 298 | 272 | $4K | |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | 259 | 200 | $3K |
| 00126 | 14 | 14 | $3K | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | 241 | 215 | $3K |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | 140 | 81 | $3K |
| 87040 | 125 | 79 | $3K | |
| 99213 | Office or other outpatient visit for the evaluation and management of an established patient, low complexity | 203 | 189 | $3K |
| 94760 | 361 | 269 | $3K | |
| 11043 | 22 | 14 | $2K | |
| 86431 | 160 | 152 | $2K | |
| 96376 | 66 | 28 | $2K | |
| 84480 | 128 | 124 | $2K | |
| 84403 | 57 | 53 | $2K | |
| 82550 | 102 | 83 | $1K | |
| 77063 | Screening digital breast tomosynthesis, bilateral | 63 | 56 | $1K |
| J8499 | Prescription drug, oral, non chemotherapeutic, nos | 507 | 277 | $1K |
| 12001 | 12 | 12 | $1K | |
| 82553 | 78 | 61 | $1K | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | 216 | 173 | $1K |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | 73 | 65 | $1K |
| 17250 | 14 | 12 | $1K | |
| 82746 | 42 | 38 | $1K | |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | 103 | 98 | $917.13 |
| L8699 | Prosthetic implant, not otherwise specified | 13 | 13 | $884.26 |
| 72100 | 13 | 12 | $860.88 | |
| 99214 | Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity | 81 | 76 | $854.47 |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | 13 | 12 | $771.42 |
| 80320 | 13 | 13 | $684.11 | |
| 86677 | 14 | 14 | $643.05 | |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | 74 | 42 | $639.37 |
| 82077 | 26 | 25 | $625.27 | |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | 14 | 13 | $616.85 |
| 87081 | 48 | 37 | $496.74 | |
| J7120 | Ringers lactate infusion, up to 1000 cc | 59 | 52 | $484.88 |
| 85007 | 96 | 86 | $458.05 | |
| 94664 | 130 | 101 | $430.36 | |
| 82962 | 67 | 53 | $254.60 | |
| 82803 | 17 | 13 | $247.89 | |
| A6449 | Light compression bandage, elastic, knitted/woven, width greater than or equal to three inches and less than five inches, per yard | 36 | 30 | $211.81 |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | 36 | 26 | $184.87 |
| 85651 | 17 | 15 | $183.87 | |
| 36600 | 17 | 12 | $56.70 | |
| Q0162 | Ondansetron 1 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen | 12 | 12 | $46.52 |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | 17 | 12 | $44.89 |
| J2270 | Injection, morphine sulfate, up to 10 mg | 18 | 13 | $39.20 |
| 81015 | 14 | 14 | $3.05 |